Jennison Associates LLC reduced its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 7.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,225 shares of the biopharmaceutical company’s stock after selling 14,745 shares during the quarter. Jennison Associates LLC owned about 0.48% of MacroGenics worth $3,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its stake in MacroGenics by 21.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 148,792 shares of the biopharmaceutical company’s stock valued at $2,606,000 after purchasing an additional 25,823 shares in the last quarter. Vanguard Group Inc. grew its position in MacroGenics by 3.4% during the first quarter. Vanguard Group Inc. now owns 1,352,864 shares of the biopharmaceutical company’s stock valued at $25,163,000 after acquiring an additional 44,680 shares during the last quarter. FMR LLC grew its position in MacroGenics by 6.0% during the second quarter. FMR LLC now owns 5,238,917 shares of the biopharmaceutical company’s stock valued at $91,733,000 after acquiring an additional 295,553 shares during the last quarter. Bank of New York Mellon Corp grew its position in MacroGenics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 159,839 shares of the biopharmaceutical company’s stock valued at $2,799,000 after acquiring an additional 25,279 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in MacroGenics by 2.2% during the second quarter. Teachers Advisors LLC now owns 322,309 shares of the biopharmaceutical company’s stock valued at $5,644,000 after acquiring an additional 6,859 shares during the last quarter. 84.72% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “MacroGenics, Inc. (MGNX) Position Trimmed by Jennison Associates LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/19/macrogenics-inc-mgnx-position-trimmed-by-jennison-associates-llc.html.

MacroGenics, Inc. (MGNX) opened at $19.20 on Friday. MacroGenics, Inc. has a fifty-two week low of $14.36 and a fifty-two week high of $29.45.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The firm’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.97) EPS. equities analysts anticipate that MacroGenics, Inc. will post -0.7 earnings per share for the current fiscal year.

A number of research analysts have commented on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $34.00 price target on shares of MacroGenics in a research report on Tuesday, September 12th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $26.00 price target on shares of MacroGenics in a research report on Friday, September 1st. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine cut shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Finally, BidaskClub upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.10.

In related news, SVP Jon Marc Wigginton sold 10,000 shares of MacroGenics stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares in the company, valued at $800,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.30% of the company’s stock.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.